$13.43 B
Share price
Change (1 day)
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Revenue for BeiGene (BGNE)

Revenue in 2022 (TTM): $0.98 B

According to BeiGene 's latest financial reports the company's current revenue (TTM) is $0.98 B. In 2021 the company made a revenue of $1.29 B an increase over the years 2020 revenue that were of $0.32 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for BeiGene from 2015 to 2022

Year Revenue Change
2022 (TTM)$0.98 B-23.87%
2021$1.29 B297.67%
2020$0.32 B14.17%
2019$0.28 B38.46%
2018$0.20 B
2015$8.81 M